Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02322086 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10
A Phase 2 study, sponsored by Provectus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02322086 is a Phase 2 study that has completed, run by Provectus Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT02322086, a Phase 2 study, has completed, sponsored by Provectus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a multicenter study of subjects with mild to moderate psoriasis. Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites). Biopsies of one target plaque will be collected at baseline (at least 7 days prior to first study treatment on Day 1) and at Days 29 and 64, with a 7-day interval between biopsy at Day 29 and commencement of application of application of active PH-10 on Day 36. Study data from each subject will serve as an internal control (i.e., assessment at baseline and at the end of application of PH-10 vehicle) for assessment of clinical and cellular response to active investigational agent.
Interventions
- DRUG Topical Rose Bengal, 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02322086
The ClinicalTrials.gov registry entry for NCT02322086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Provectus Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topical Rose Bengal, 0.005% is the first listed.
NCT02322086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02322086 about?
NCT02322086 is a clinical study titled "A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10". This is a multicenter study of subjects with mild to moderate psoriasis. Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and inter...
What is the current status of trial NCT02322086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2015-01. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02322086?
The interventions under investigation include: Topical Rose Bengal, 0.005% (DRUG).
Who is sponsoring clinical trial NCT02322086?
This trial is sponsored by Provectus Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.